E 7016

Drug Profile

E 7016

Alternative Names: E-7016; GPI-21016

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator MGI GP
  • Developer Eisai Co Ltd
  • Class Antineoplastics
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glioma; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Late-stage disease) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO)
  • 31 Mar 2012 Phase-II clinical trials in Malignant melanoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top